This week we've had eyes on BioPharma happenings plus a 2023 Top Selling Drugs list.

We've had Eyes On recent news further clarifying company restructures. In the midst of refining pipelines, and cutting corporate spending ..

We've been keeping Eyes On Deals & Raises in the BioPharma sector for the first quarter of 2024. Things seem to be heating-up ...

Lately we've been keeping Eyes On the corporate restructuring in the BioPharma sector. We've seen Big Pharma and BioTech refocusing ...

We've been trying to keep up with current events - here's some of what we've hay Eyes On this week.

Some of the highlights include AI medical advancements, strategic industry movements, regulatory updates, & challenges within the pharma ...

This week we've had Eyes how BioPharma are bolstering their Portfolios for long-term success. From licensing assets ...

Some of this week's news includes Casgevy Approval, Novo's REDEFINE 4 Trial, , new Manufacturing plant and more.

While we've been curating 3Q23 Results reports, we've had eyes on drug approvals, Business Development activities, & even some patent ...

After all the quarterly results reporting, we've had eyes on product approvals, resubmissions, and a withdrawal.

This week PharmaTell had Eyes On: Heartburn – the kind caused by the upcoming Zantac litigation & resulting market jitters.